Mateon Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
95.00
-
-
-
-
2
Cost of Goods Sold (COGS) incl. D&A
-
109.00
20.00
19.00
9.00
2
Gross Income
-
109.00
20.00
19.00
9.00
2
SG&A Expense
8,265.00
12,541.00
13,662.00
13,740.00
13,833.00
3,000
EBIT
8,280.00
12,650.00
13,682.00
13,759.00
13,842.00
3,002
Non Operating Income/Expense
1.00
3.00
1.00
1.00
5.00
1
Pretax Income
8,277.00
12,647.00
13,654.00
13,654.00
13,812.00
2,737
Consolidated Net Income
8,277.00
12,647.00
13,654.00
13,654.00
13,812.00
2,737
Net Income
8,277.00
12,647.00
13,654.00
13,654.00
13,812.00
2,737
Net Income After Extraordinaries
8,277.00
12,647.00
13,654.00
13,654.00
13,812.00
2,737
Net Income Available to Common
13,076.00
12,647.00
13,654.00
13,654.00
13,812.00
2,737
EPS (Basic)
4.67
0.75
0.54
0.51
0.52
0.07
Basic Shares Outstanding
2,803.00
16,973.00
25,201.00
26,545.00
26,545.00
37,251
EPS (Diluted)
4.67
0.75
0.54
0.51
0.52
0.07
Diluted Shares Outstanding
2,803.00
16,973.00
25,201.00
26,545.00
26,545.00
37,251
EBITDA
8,170.00
12,541.00
13,662.00
13,740.00
13,833.00
3,000
Non-Operating Interest Income
4.00
6.00
27.00
106.00
35.00
16
Preferred Dividends
4,799.00
-
-
-
-
-
About Mateon Therapeutics
View Profile
